| INTRODUCTION
Gastric cancer (GC) is a leading cause of malignancy-related death globally. 1 Despite improvements in the treatment outcomes, GC prognosis is generally poor, with a 5-year relative survival rate remaining below 30% in most countries. 2 Surgical resection is the only treatment with curative intent, whereas postoperative chemotherapy was observed to improve GC prognosis after surgery 3 ;
however, most GC patients are not eligible for radical surgery due to the locally advanced or metastatic disease. 4 Thus, the identification of novel useful prognostic markers and therapeutic targets for GC treatment is essential.
Transforming growth factor β-induced (TGFBI) protein is a secreted extracellular matrix protein consisting of 683 amino acids and includes four evolutionarily conserved fasciclin-1 domains and a C-terminal Arg-Gly-Asp motif. 5 TGFBI was first described in a human lung adenocarcinoma cell line in 1992 as a protein that was inducible by transforming growth factor β (TGFβ), 6 which was confirmed in various human cell types since its discovery. 7, 8 TGFBI was reported to play important roles in various clinical conditions such as malignancy, diabetes, and corneal dystrophy. [9] [10] [11] In malignancies, TGFBI was revealed to perform conflicting roles, acting both as a tumour suppressor and a promoter. TGFBI downregulation was observed in leukaemia, 12 whereas hypermethylation of the TGFBI promoter, which suppresses TGFBI expression, was observed in the ovarian, prostate, and lung carcinomas. 13, 14 These findings ascribe certain tumour-suppressor functions to TGFBI. Conversely, TGFBI was also known to exert tumour-promoter functions in various cancers. TGFBI upregulation was reported in pancreatic carcinoma and oral squamous cell carcinoma, 7, 15 whereas in renal cell carcinoma, TGFBI expression was revealed as a promising prognostic marker. 16 Regarding GC, the transgenic mice overexpressing TGFBI developed spontaneous gastric adenocarcinoma at a high rate than wild-type mice 9 ; however, few studies investigated the role of TGFBI in human GC specimens in detail. Figure 1 ).
| Cell lines
The human GC cell lines MKN7, MKN45, MKN74, and GCIY, as well as the gastric fibroblast cell lines CAF64, CAF61, and NF64, were used in this study. MKN7, MKN45, and MKN74 were purchased from the JCRB Cell Bank (Osaka, Japan), and GCIY was purchased from RIKEN BRC (Tokyo, Japan). All gastric cell lines were maintained in Roswell Park Memorial Institute 1640 medium (Wako, Osaka, Japan) supplemented with 10% foetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA).
Gastric fibroblast cell lines were isolated from surgical specimens at Osaka City University. CAF64 and CAF61 originated from the fibroblasts of GC tissues, and NF64 originated from the normal gastric tissue; both cell lines were maintained in Dulbecco modified
Eagle medium (DMEM; Wako) supplemented with 10% FBS and 1%
penicillin-streptomycin (Invitrogen). Precise protocols used to establish the fibroblast cell lines were described in a previous report. 18 All cell lines were cultured in a humidified incubator with 5% CO 2 at 37°C. 
| Cell invasion assay
Invasion ability of MKN7 and MKN45 cells was analysed using with phosphate-buffered saline, and cleaned using a cotton swab.
Cells were then fixed in methanol and stained with the Diff-Quick stain (Sysmex, Kobe, Japan). Membranes were cut and observed under ×100 magnification using bright field microscopy. and 24 hour (MKN45) after the wound creation at ×40 magnification using bright field microscopy. samples were classified into the high TGFBI-expression group.
| Statistical analysis
The relationship of stromal TGFBI expression with clinicopathological factors in this cohort of 208 GC patients is presented in Table 2 . High TGFBI expression was significantly associated with depth of tumour invasion (P < 0.001), lymphatic invasion (P = 0.001), venous invasion (P = 0.046), peritoneal dissemination (P = 0.045), and pathological stage (P < 0.001).
The Kaplan-Meier analysis of data from 208 GC patients demonstrated that the overall survival in the high TGFBI-expression group was significantly lower than that in the low TGFBI-expression group (P = 0.0016; Figure 2 ).
Univariate regression analyses for overall survival among the cohort of 208 GC samples indicated that the depths of tumour invasion (P < 0.0001), lymph node metastasis (P < 0.0001), lymphatic invasion (P = 0.0014), venous invasion (P < 0.0001), peritoneal dissemination (P = 0.0008), pathological stage (P < 0.0001), and TGFBI expression (P = 0.0039) were significantly associated with poor prognosis; however, multivariate analysis indicated that high TGFBI expression was not an independent predictor for poor prognosis (Table 3) . TGFBI expression was higher in CAF64 cells than the other fibroblast cell lines. Therefore, the CAF64 cell line was used to clarify whether TGFBI in fibroblasts contributed to the malignant phenotype in two GC cell lines: MKN7 and MKN45, which were derived from welldifferentiated and poorly-differentiated adenocarcinomas, respectively.
| CAF64 cells upregulated the invasion and migration abilities of cocultured MKN7 and MKN45 cells
To evaluate the effect of CAF64 cells on GC cells, we performed an invasion and wound-healing assay in a coculture model. The 
| DISCUSSION
In this study, we found that TGFBI was expressed primarily in cancer stroma and not in the GC cells or noncancerous tissue. We also reported that high TGFBI levels in cancer stroma correlated with that fibroblasts around GC were associated with aggressiveness of GC cells via the TGF-β signalling. 23 Therefore, we suggest that TGFBI might be derived from gastric stromal fibroblasts via activation of the TGF-β signalling, in contrast to the GC cells.
TGFBI has been observed to serve contradictory functions in tumorigenesis. 24 Although TGFBI was reported to function as a tumour suppressor in leukaemia and ovarian, prostate, and lung carcinomas, [12] [13] [14] the tumour-promoting role of TGFBI was indicated in renal cell carcinoma, pancreatic carcinoma, oral and oesophageal squamous cell carcinoma, and colon carcinoma. 7, 1615, 19, 25 Furthermore, Han et al 9 reported a role for TGFBI in tumorigenesis of the gastrointestinal tract 9 by demonstrating that TGFBI overexpression increased the incidence of spontaneous tumours including gastric adenocarcinoma in transgenic mice. In this study, we reported that high stromal TGFBI expression correlated with cancer progression and poor prognosis in clinical GC samples, suggesting that stromal TGFBI was acting as a tumour promoter in gastric tissue. Moreover, TGFBI expression might be a useful marker in predicting cancer progression and poor prognosis in GC.
In the current study, high stromal TGFBI expression was significantly correlated with peritoneal dissemination. Peritoneal dissemination is widely recognised as the most important and difficult therapeutic target in progressive GC phenotype. 26 Although various strategies including systemic chemotherapy, intraperitoneal chemotherapy, hyperthermia, and aggressive surgery have been used to control peritoneal dissemination, their clinical benefits are limited. 27, 28 Intraperitoneal paclitaxel administration in GC patients with peritoneal dissemination has been recently gaining attention as intraperitoneal paclitaxel is expected to remain inside the peritoneal cavity due to its large molecular weight and fat solubility. 29 Paclitaxel is also used as a standard treatment in ovarian cancer. 30 Wang et al 31 reported that silencing TGFBI by hypermethylation of its promoter correlated with paclitaxel resistance in ovarian cancer. 31 Moreover, Ahmed et al 32 that TGFBI knockdown led to growth inhibition through defective cell cycle progression in the melanoma cells. Specifically, they demonstrated that TGFBI was a regulator of cyclins and cyclin-dependent kinases that control the progression of cell cycle and cancer aggressiveness in several cancer types including GC. 33 Based on these observations, we
propose that TGFBI localised in the GC stroma might be a promising target for therapeutic intervention through its ability to inhibit the invasion and migration abilities and cell cycle progression of cancer cells.
| CONCLUSIONS
TGFBI expression in the cancer stromal cells was associated with poor prognosis and cancer progression in GC patients. In an in vitro model, TGFBI expressed by fibroblasts regulated the invasion and migration abilities of the GC cells, which might be related to cancer progression. TGFBI expression is a potentially useful predictive marker for poor prognosis in GC. Moreover, TGFBI in the cancer stromal cells is a promising therapeutic candidate to improve prognosis in the GC patients.
